Selling, General, and Administrative Costs: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.

SG&A Expenses: Taro's Aggressive Growth vs. Xencor's Steady Rise

__timestampTaro Pharmaceutical Industries Ltd.Xencor, Inc.
Wednesday, January 1, 2014917330007461000
Thursday, January 1, 20158764400011960000
Friday, January 1, 20169236500013108000
Sunday, January 1, 20178565600017501000
Monday, January 1, 20188819600022472000
Tuesday, January 1, 20198997100024286000
Wednesday, January 1, 20209341300029689000
Friday, January 1, 20219135500038837000
Saturday, January 1, 202211367600047489000
Sunday, January 1, 202319836600053379000
Monday, January 1, 2024218935000
Loading chart...

Unveiling the hidden dimensions of data

A Comparative Analysis of SG&A Expenses: Taro vs. Xencor

In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Taro Pharmaceutical Industries Ltd. and Xencor, Inc. over the past decade.

Taro has consistently outpaced Xencor in SG&A spending, with a notable increase of over 130% from 2014 to 2023. In 2023, Taro's expenses surged to nearly double their 2022 figures, highlighting a strategic shift or expansion. In contrast, Xencor's expenses grew steadily, peaking in 2023 with a 617% increase since 2014.

This trend underscores Taro's aggressive market strategies compared to Xencor's more conservative approach. However, the absence of data for 2024 suggests potential changes in reporting or strategic pivots. Understanding these dynamics is essential for investors and stakeholders aiming to navigate the pharmaceutical sector's complexities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025